We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cannabis Operator Green Thumb Down 30% YTD: Time to Buy, Sell or Hold?
Read MoreHide Full Article
Key Takeaways
Green Thumb's Q1 sales rose just 1% to $280M, with retail sales down 2.5% amid price compression.
GTBIF's margins declined as pricing pressure and rising costs dragged EPS below expectations.
Q2 outlook calls for flat revenues and EBITDA margins staying under 30% amid persistent headwinds.
Despite being one of the largest cannabis operators by market capitalization, shares of Green Thumb Industries (GTBIF - Free Report) have been declining persistently over the past few years due to regulatory hurdles and intensifying competition.
While the company’s top-line growth seems encouraging, profitability remains under pressure from rising costs.
Let’s delve into the company’s fundamentals to gain a better understanding of how to play the stock amid this price decline.
Pricing Pressures on GTBIF’s Operations: A Woe
What sets Green Thumb apart from many peers is its vertically integrated model — cultivating, processing and selling cannabis through its own retail and wholesale operations. However, with 100% of the company’s revenues tied to U.S. markets, it remains highly exposed to domestic regulatory risks, particularly the lack of federal legalization, which continues to restrict access to capital and interstate commerce.
Green Thumb’s first-quarter 2025 top-line numbers rose just 1% year over year to $280 million. While the company’s consumer packaged goods (CPG) business delivered 14% year-over-year growth, the gains were partially offset by a 2.5% decline in retail segment sales due to price compression in existing markets. Sales of comparable stores (open at least 12 months) fell more than 5% during the quarter, reflecting competitive pressure and softer consumer demand.
However, the company’s bottom line painted a more challenging picture. Despite the nearly flat sales, profitability came under strain. Gross profit margins during the quarter were 51.3%, down 80 basis points from the year-ago period’s level due to the pricing compression.
Meanwhile, selling and operating expenses rose 11%, and the company reported a sharply higher effective tax rate of 79% (vs. 51% in the year-ago period). These cost pressures contributed to a significant hit to net income and EPS, with GTBIF missing our consensus estimate.
Looking ahead, we expect Green Thumb to remain under pressure due to persistent pricing compression in maturing markets. Management has already flagged expectations for flat sequential revenue growth in the second quarter and noted that adjusted EBITDA margins are likely to remain below the 30% mark in the near term. While the company continues to prioritize cash flow and prudent cost management, margin expansion could remain elusive without meaningful regulatory reform or a rebound in retail pricing dynamics.
Stiff Competition From Other Cannabis Players
Green Thumb is targeting an overcrowded market. It faces stiff competition from its peers — Aurora Cannabis (ACB - Free Report) , Cresco Labs (CRLBF - Free Report) and Curaleaf Holdings (CURLF - Free Report) — all of which are also pursuing similar expansion and cost-optimization strategies, making the competitive landscape even tougher.
Companies like Aurora Cannabis and Curaleaf Holdings are also expanding their footprints beyond geographic borders, in markets like Europe and Australia. This international exposure gives them an edge over Green Thumb and Cresco Labs, who remain fully dependent on an increasingly saturated and fragmented U.S. market.
GTBIF Stock Performance and Estimates
Shares of Green Thumb have declined 30% year to date against the industry’s 5% growth, as shown in the chart below.
Image Source: Zacks Investment Research
While EPS estimates for 2025 have declined slightly, the same for 2026 have been stable over the past 60 days.
Image Source: Zacks Investment Research
How to Play GTBIF Stock?
While a stable revenue stream and ability to generate free cash flow offer some support for GTBIF stock, the stock remains exposed to significant domestic headwinds. However, the company’s significant exposure to the domestic market, combined with rising costs and margin pressures, continues to strain its financial profile. Without a major shift in federal policy or a recovery in retail pricing, meaningful upside appears limited.
With its earnings trajectory under pressure and no international diversification to help offset domestic headwinds, the investment case for GTBIF remains weak for risk-averse investors. A Zacks Rank #4 (Sell) further reflects that the stock offers limited upside and elevated risk for conservative investors.
Image: Bigstock
Cannabis Operator Green Thumb Down 30% YTD: Time to Buy, Sell or Hold?
Key Takeaways
Despite being one of the largest cannabis operators by market capitalization, shares of Green Thumb Industries (GTBIF - Free Report) have been declining persistently over the past few years due to regulatory hurdles and intensifying competition.
While the company’s top-line growth seems encouraging, profitability remains under pressure from rising costs.
Let’s delve into the company’s fundamentals to gain a better understanding of how to play the stock amid this price decline.
Pricing Pressures on GTBIF’s Operations: A Woe
What sets Green Thumb apart from many peers is its vertically integrated model — cultivating, processing and selling cannabis through its own retail and wholesale operations. However, with 100% of the company’s revenues tied to U.S. markets, it remains highly exposed to domestic regulatory risks, particularly the lack of federal legalization, which continues to restrict access to capital and interstate commerce.
Green Thumb’s first-quarter 2025 top-line numbers rose just 1% year over year to $280 million. While the company’s consumer packaged goods (CPG) business delivered 14% year-over-year growth, the gains were partially offset by a 2.5% decline in retail segment sales due to price compression in existing markets. Sales of comparable stores (open at least 12 months) fell more than 5% during the quarter, reflecting competitive pressure and softer consumer demand.
However, the company’s bottom line painted a more challenging picture. Despite the nearly flat sales, profitability came under strain. Gross profit margins during the quarter were 51.3%, down 80 basis points from the year-ago period’s level due to the pricing compression.
Meanwhile, selling and operating expenses rose 11%, and the company reported a sharply higher effective tax rate of 79% (vs. 51% in the year-ago period). These cost pressures contributed to a significant hit to net income and EPS, with GTBIF missing our consensus estimate.
Looking ahead, we expect Green Thumb to remain under pressure due to persistent pricing compression in maturing markets. Management has already flagged expectations for flat sequential revenue growth in the second quarter and noted that adjusted EBITDA margins are likely to remain below the 30% mark in the near term. While the company continues to prioritize cash flow and prudent cost management, margin expansion could remain elusive without meaningful regulatory reform or a rebound in retail pricing dynamics.
Stiff Competition From Other Cannabis Players
Green Thumb is targeting an overcrowded market. It faces stiff competition from its peers — Aurora Cannabis (ACB - Free Report) , Cresco Labs (CRLBF - Free Report) and Curaleaf Holdings (CURLF - Free Report) — all of which are also pursuing similar expansion and cost-optimization strategies, making the competitive landscape even tougher.
Companies like Aurora Cannabis and Curaleaf Holdings are also expanding their footprints beyond geographic borders, in markets like Europe and Australia. This international exposure gives them an edge over Green Thumb and Cresco Labs, who remain fully dependent on an increasingly saturated and fragmented U.S. market.
GTBIF Stock Performance and Estimates
Shares of Green Thumb have declined 30% year to date against the industry’s 5% growth, as shown in the chart below.
Image Source: Zacks Investment Research
While EPS estimates for 2025 have declined slightly, the same for 2026 have been stable over the past 60 days.
Image Source: Zacks Investment Research
How to Play GTBIF Stock?
While a stable revenue stream and ability to generate free cash flow offer some support for GTBIF stock, the stock remains exposed to significant domestic headwinds. However, the company’s significant exposure to the domestic market, combined with rising costs and margin pressures, continues to strain its financial profile. Without a major shift in federal policy or a recovery in retail pricing, meaningful upside appears limited.
With its earnings trajectory under pressure and no international diversification to help offset domestic headwinds, the investment case for GTBIF remains weak for risk-averse investors. A Zacks Rank #4 (Sell) further reflects that the stock offers limited upside and elevated risk for conservative investors.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.